Opportunity Information: Apply for CDC RFA GH15 15820201SUPP16
Apply for CDC RFA GH15 15820201SUPP16
- The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Program Expansion Supplement: Strengthening Local Capacity to Deliver Sustainable Quality-Assured Universal Coverage of Clinical HIV/TB Services and Provide Central Level Technical Assistance in Swaziland Natl AIDS Program under PEPFAR" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067.
- This funding opportunity was created on Aug 05, 2016.
- Applicants must submit their applications by Oct 04, 2016 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $355,549.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity is a PEPFAR-supported program expansion supplement from the U.S. Centers for Disease Control and Prevention (CDC) that focuses on strengthening Swaziland's capacity to deliver high-quality, sustainable, and integrated HIV and TB clinical services. It is framed as a cooperative agreement, meaning the CDC would expect to have substantial involvement in implementation and oversight, rather than simply issuing a grant with minimal engagement. The opportunity responds to the reality that Swaziland faces one of the worlds most intense dual HIV/TB epidemics, with extremely high adult HIV incidence (estimated around 2.4 annually), very high HIV prevalence among adults ages 18-49 (about 31 percent), and an exceptionally high TB incidence rate (about 1,380 per 100,000 people). The burden is compounded by the fact that roughly three-quarters to four-fifths of TB cases are co-infected with HIV, and HIV prevalence among pregnant women is reported at about 41 percent, highlighting ongoing transmission and major risks for mothers and infants.
The core problem the supplement is trying to solve is the gap between progress already made and what is still needed to reach universal coverage under newer WHO 2013 recommendations. Swaziland has advanced its HIV/TB response, but the country still needs stronger, more consistent service delivery across the full clinical continuum: HIV testing, linkage to care, antiretroviral treatment, retention, and integrated TB services. The opportunity explicitly emphasizes building sustainable stewardship and technical capacity within the Ministry of Health (MOH) at national, regional, and facility levels, so improvements are not temporary or dependent on outside actors. It also supports Swazilands planned rollout of viral load monitoring and the shift to test and start ART, in line with updated global guidance aimed at starting treatment earlier and using viral load results to ensure treatment effectiveness and reduce transmission.
The funding aligns with goals described in Swazilands extended National Strategic Framework (eNSF). Those priorities include getting all children, adolescents, women, and men tested and aware of their HIV status; improving access and use of prevention and treatment services for key populations; eliminating new pediatric infections while keeping mothers alive; and improving the quality of life for people living with HIV by strengthening treatment both as clinical care and as a prevention strategy. In practical terms, the supplement is designed to help translate these strategic goals into operational changes at health facilities, with a strong emphasis on quality assurance and the ability of the health system to sustain these services.
The supplement has two main funding purposes. First, it supports viral load scale-up by funding training for clinical staff and by procuring supplies needed to manage viral load results at the facility level. This is not just about running tests; it is about making sure providers know how to interpret results, respond to unsuppressed viral load with appropriate clinical action (such as enhanced adherence counseling or regimen adjustments), and maintain reliable patient monitoring systems. Second, it expands test and start services to improve immediate ART initiation and strengthen linkage and retention, with a particular focus on reaching and keeping male clients in care. The opportunity notes that men are of special concern because many do not engage with traditional clinic-based services, so the program encourages more male-friendly approaches. Examples mentioned include extending clinic hours and using community outreach to reduce access barriers and improve continuity of care.
Geographically, the supplement targets the Lubombo region and specifically references 34 facilities where these changes are expected to be implemented. The application makes a concrete case for the impact of not funding this expansion: an estimated 11,495 HIV-positive clients in these facilities could miss viral load monitoring, and about 137 HIV-positive individuals could lose access to immediate treatment under a test and start approach. While those numbers are framed as potential consequences of a funding gap, they also function as implied target populations and performance stakes for the supplemental investment.
Administratively, this opportunity is listed as CDC RFA GH15-15820201SUPP16 under CFDA 93.067, categorized as discretionary funding and issued by the Department of Health and Human Services, CDC (Center for Global Health). It was posted on Aug 05, 2016, with an application deadline of Oct 04, 2016 (11:59 p.m. ET for electronic submissions). The award ceiling is $355,549, with one expected award, which signals it is likely a targeted supplement to expand or enhance an existing implementing mechanism rather than a broad open competition for multiple new awards. Eligibility is listed as "Others" with additional eligibility details referenced outside the excerpt, which often indicates limited eligibility (for example, current recipients or specific partner organizations) typical of expansion supplements.
Overall, the opportunity is best understood as a focused investment to accelerate two high-impact clinical upgrades in Swaziland: routine viral load monitoring and immediate treatment initiation, delivered through strengthened facility systems and MOH stewardship. It also highlights a practical service delivery gap that often undermines HIV program outcomes: retention in care, especially among men. By pairing technical components (training, supplies, clinical monitoring workflows) with access and retention strategies (expanded hours, outreach, male-friendly services), the supplement aims to improve both the quality and the reach of HIV/TB clinical care in a high-burden setting.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is a PEPFAR-supported program expansion supplement from the U.S. Centers for Disease Control and Prevention (CDC). It focuses on strengthening Swaziland's capacity to deliver high-quality, sustainable, and integrated HIV and TB clinical services.
Is this a grant or something else?
It is structured as a cooperative agreement. That means CDC expects substantial involvement in implementation and oversight, rather than issuing funding with minimal ongoing engagement.
Why is CDC funding this supplement in Swaziland?
The supplement responds to Swaziland's severe dual HIV/TB epidemic. The description highlights extremely high adult HIV incidence (estimated around 2.4 annually), high HIV prevalence among adults ages 18-49 (about 31 percent), and very high TB incidence (about 1,380 per 100,000). It also notes that roughly three-quarters to four-fifths of TB cases are co-infected with HIV, and HIV prevalence among pregnant women is reported at about 41 percent.
What gap is the supplement trying to address?
The focus is on closing the gap between progress already made and what is still needed to reach universal coverage under newer WHO 2013 recommendations. The opportunity emphasizes strengthening consistent service delivery across the HIV clinical continuum (testing, linkage to care, ART, retention) and integrated TB services.
What are the main program goals described in the opportunity?
The opportunity aims to strengthen Swaziland's clinical HIV/TB service delivery while building sustainable stewardship and technical capacity within the Ministry of Health (MOH) at national, regional, and facility levels. It also supports planned rollout of viral load monitoring and adoption of a test and start approach for antiretroviral treatment (ART).
How does this opportunity relate to Swaziland's national strategy?
The funding aligns with goals in Swaziland's extended National Strategic Framework (eNSF). Priorities described include increasing HIV testing and awareness of status; improving prevention and treatment access for key populations; eliminating new pediatric infections while keeping mothers alive; and improving quality of life for people living with HIV through stronger treatment services and treatment as prevention.
What are the two main funding purposes of the supplement?
The supplement has two primary purposes: (1) supporting viral load scale-up through training and procurement of supplies needed to manage viral load results at facilities; and (2) expanding test and start services to improve immediate ART initiation and strengthen linkage and retention, with particular attention to male clients.
What does "viral load scale-up" mean in this opportunity?
In the context provided, viral load scale-up is more than conducting tests. It includes training providers to interpret viral load results, take appropriate clinical action when viral load is not suppressed (such as enhanced adherence counseling or regimen adjustments), and maintain reliable patient monitoring systems at the facility level.
What does "test and start" mean in this opportunity?
Test and start refers to initiating ART immediately after an HIV diagnosis, consistent with updated global guidance mentioned in the opportunity. The supplement supports expanding these services to strengthen immediate initiation, linkage, and retention in care.
Why is there a special focus on men?
The opportunity describes men as a group of special concern because many do not engage with traditional clinic-based services. The supplement encourages more male-friendly approaches to reduce barriers and improve retention.
What examples of male-friendly approaches are mentioned?
Examples included in the description are extending clinic hours and using community outreach to reduce access barriers and improve continuity of care for male clients.
Where will the supplement be implemented?
The supplement targets the Lubombo region and specifically references 34 facilities where the supported changes are expected to be implemented.
How many people could be affected if this expansion is not funded?
The opportunity states that without funding, an estimated 11,495 HIV-positive clients in the referenced facilities could miss viral load monitoring, and about 137 HIV-positive individuals could lose access to immediate treatment under a test and start approach.
Which agency and department are issuing this opportunity?
It is issued by the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), Center for Global Health.
What is the funding opportunity number and CFDA listing?
The opportunity is listed as CDC RFA GH15-15820201SUPP16 under CFDA 93.067.
What type of funding is this categorized as?
It is categorized as discretionary funding.
How much funding is available?
The award ceiling listed is $355,549.
How many awards are expected?
One award is expected, suggesting this is likely a targeted supplement to expand or enhance an existing implementing mechanism.
Who is eligible to apply?
Eligibility is listed as "Others," with additional eligibility details referenced outside the provided excerpt. The description notes that this often indicates limited eligibility typical of expansion supplements (for example, current recipients or specific partner organizations), but the excerpt itself does not provide the exact limitations.
When was the opportunity posted and what was the application deadline?
It was posted on Aug 05, 2016. The application deadline was Oct 04, 2016, with electronic submissions due by 11:59 p.m. ET.
What is the overall intent of the supplement?
The opportunity is framed as a focused investment to accelerate two clinical upgrades in Swaziland: routine viral load monitoring and immediate treatment initiation. It pairs technical improvements (training, supplies, monitoring workflows) with access and retention strategies (expanded hours, outreach, male-friendly services), while emphasizing MOH stewardship and sustainability.
Browse more opportunities from the same agency: Department of Health and Human Services, Centers for Disease Control - CGH
Browse more opportunities from the same category: Health
Next opportunity: Sound and Light Ecology Research
Previous opportunity: Polio Eradication and Emergency Response in Priority Countries
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH15 15820201SUPP16
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH15 15820201SUPP16) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cooperative Agreement on Immunization with United Nations Children's Fund (UNICEF) Apply for CDC RFA GH13 13020401SUPP16 Funding Number: CDC RFA GH13 13020401SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Program Expansion Supplement: Support for Strengthening and Expanding HIV/AIDS Surveillance Activities in SA under PEPFAR Apply for CDC RFA GH11 11540501SUPP16 Funding Number: CDC RFA GH11 11540501SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $3,500,000 |
| Delivering Comprehensive Services to Achieve HIV Epidemic Control in Subnational Units in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1753 Funding Number: CDC RFA GH17 1753 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $200,000,000 |
| Building the Capacity of the Government of Suriname to Address Gaps in the HIV Continuum of Care for Key Populations and People Living with HIV (PLHIV) under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1774 Funding Number: CDC RFA GH17 1774 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $300,000 |
| Program Expansion Supplement for Planning, Implementation and Evaluation of Comprehensive HIV Prevention Programs in South Africa under PEPFAR Apply for CDC RFA GH11 11520501SUPP16 Funding Number: CDC RFA GH11 11520501SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $3,604,705 |
| Supporting Local Indigenous Faith-Based Partners in Providing High Quality HIV Care, Prevention and Treatment Services and Improving Linkage and Retention in the Republic of Guyana under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1721 Funding Number: CDC RFA GH17 1721 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $465,000 |
| Support for Quality Facility and Community-based Antiretroviral Therapy (ART) for Adults and Children in Cameroon under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1718 Funding Number: CDC RFA GH17 1718 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $10,000,000 |
| Strengthening Care and Support Services for Highly Vulnerable Populations, Orphans and Vulnerable Children and their Families, plus HIV Prevention for Youth in the Republic of Cote d'Ivoire under PEPFAR Apply for CDC RFA GH17 1755 Funding Number: CDC RFA GH17 1755 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $18,000,000 |
| Projecto de Saúde Para Todos (Health for All, or HFA) Apply for NFO RFA 654 16 000004 Funding Number: NFO RFA 654 16 000004 Agency: Agency for International Development, South Africa USAID-Pretoria Category: Health Funding Amount: $63,000,000 |
| Program Expansion Supplement: Scaling up Voluntary Medical Male Circumcision through improvement in HIV prevention under PEPFAR Apply for CDC RFA GH13 13280401SUPP16 Funding Number: CDC RFA GH13 13280401SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $3,000,000 |
| Human Heredity and Health in Africa (H3Africa): Coordinating Center (U24) Apply for RFA RM 16 017 Funding Number: RFA RM 16 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $400,000 |
| Human Heredity and Health in Africa (H3Africa): Informatics Network (U24) Apply for RFA RM 16 011 Funding Number: RFA RM 16 011 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Vector Control Strategies- Enhancing Capacity for Vector Surveillance and Control to Prevent Zika, Dengue and Chikungunya Infection in Puerto Rico - Financed in part by Prevention and Public Health Funds Apply for CDC RFA CK16 1608PPHF2016 Funding Number: CDC RFA CK16 1608PPHF2016 Agency: Department of Health and Human Services, Centers for Disease Control - NCEZID Category: Health Funding Amount: Case Dependent |
| Addressing Ebola and other Highly Infectious Diseases Internationally Apply for CDC RFA CK15 15050104SUPP16 Funding Number: CDC RFA CK15 15050104SUPP16 Agency: Department of Health and Human Services, Centers for Disease Control - NCEZID Category: Health Funding Amount: Case Dependent |
| Assist the Ministry of Health to Provide Critical Human Resources for Health to Achieve HIV Epidemic Control in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1715 Funding Number: CDC RFA GH17 1715 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $900,000 |
| Support for the National Blood Bank Services in the Implementation and Expansion of Blood Safety Activities in Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1746 Funding Number: CDC RFA GH17 1746 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $1,650,000 |
| Strengthening Capacity of HIV/AIDS Treatment in Ukraine under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1761 Funding Number: CDC RFA GH17 1761 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $1,600,000 |
| Enhancing Sustainable and Integrated Health, Strategic Information and Laboratory Systems for Quality Comprehensive HIV Services through Technical Assistance to the Republic of Rwanda under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1750 Funding Number: CDC RFA GH17 1750 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $720,000 |
| Strengthening Local Ownership and Sustainable Provision of Quality Comprehensive HIV/AIDS Services for Inmates in the Federal Prison Administration (FPA) and Regional Prisons of Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH17 1777 Funding Number: CDC RFA GH17 1777 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $500,000 |
| Hypertension Outcomes for T4 REsearch within Lower Middle-Income Countries (Hy-TREC) (U01) Apply for RFA HL 17 014 Funding Number: RFA HL 17 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $268,500 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH15 15820201SUPP16", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.